	Application No.	Applicant(s)
Notice of Allowability	10/659,164	BACQUE ET AL.
	Examiner	Art Unit
	Janet L. Coppins	1626
The MAILING DATE of this communication apperatus All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	ears on the cover sheet with the c (OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to 3 and MPEP 1308.	correspondence address oplication. If not included n will be mailed in due course. THIS
1. This communication is responsive to <u>Applicants' Amendment</u>	<u>ant of January 25, 2007.</u>	
2. The allowed claim(s) is/are <u>1-16 and 19-24</u> .		
 3. Acknowledgment is made of a claim for foreign priority uner a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 	e been received.	
Copies of the certified copies of the priority documents have		
International Bureau (PCT Rule 17.2(a)).		ridional stage application from the
* Certified copies not received:		}
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	of this communication to file a reply IENT of this application.	complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be submi	itted. Note the attached EXAMINER es reason(s) why the oath or declara	'S AMENDMENT or NOTICE OF ation is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) \square including changes required by the Notice of Draftspers	on's Patent Drawing Review (PTO-	-948) attached
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date		,
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	he header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
·	•	
	•	
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	atent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	(PTO-413),
 Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 	Paper No./Mail Dat 7. ☐ Examiner's Amendn	e nent/Comment
 Examiner's Comment Regarding Requirement for Deposit of Biological Material 	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
	9. Other	
	·	

Application/Control Number: 10/659,164

Art Unit: 1626

DETAILED ACTION

Page 2

1. Claims 1-16 and 19-24 are pending in the instant application.

Information Disclosure Statement

2. Applicants' Information Disclosure Statement (IDS), submitted January 25, 2007, has been considered by the Examiner. Please refer to the signed copy of Applicants' PTO-1449 form submitted herewith.

Response to Amendment

3. Applicants' Amendment, submitted January 25, 2007, has been entered. Accordingly, claims 17 and 18 have been cancelled, and claim 16 has been amended. In view of Applicants' amendatory changes, claims 1-16 and 19-24 are now allowable over the prior art.

REASONS FOR ALLOWANCE

4. In view of Applicant's amendatory changes and cancellations, claims 1-16 and 19-24 are allowable over the prior art, as newly renumbered claims 1-22. The following is an examiner's statement of reasons for allowance:

This invention relates to novel quinolylpropyl-piperidine derivatives, their pharmaceutical compositions, their processes of preparation, and their methods of use. The allowable compounds are limited to compounds according to formula I of claim 1, compounds of formula (II) of claim 12, compounds of formula (A) of claim 15, compounds of formula (B) of claim 16, and compounds of formula (VIII) of claim 19. Certain quinolylpropyl-piperidine compounds are known in the art, however the aspect of preparing the instant claimed quinolylpropyl-piperidine derivatives, with antimicrobial activity, is novel and unobvious. After a thorough search, the closest of prior art, the Grethe, et al. journal article, was found to teach

Art Unit: 1626

similar quinolylpropyl-piperidine derivatives. However the Grethe journal article fails to teach or render obvious the instant claimed compounds according to claimed formulae (I), (II), (A), (B) or (VIII), and does not fairly suggest methods of using the instant claimed compounds as antimicrobials.

Page 3

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Coppins whose telephone number is 571.272.0680. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph K. McKane can be reached on 571.272.0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/659,164

Art Unit: 1626

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Janet L. Coppins February 19, 2007

Joseph K. M^cKane

SPE, Art Unit 1626

KAMALA. SAEEZ, FII.D. PRIMARY EXAMINER